Antimicrobial Susceptibility and Molecular Characterization of Carbapenem-Resistant Klebsiella pneumoniae from United States Medical Centers (2020–2025)
Antimicrobial Susceptibility and Molecular Characterization of Carbapenem-Resistant Klebsiella pneumoniae from United States Medical Centers (2020–2025). Lead author: Helio S. Sader, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-75
Aztreonam-avibactam activity against Enterobacterales from United States medical centers: Summary of 5 years of surveillance prior to approval for clinical use (2020–2024)
Aztreonam-avibactam activity against Enterobacterales from United States medical centers: Summary of 5 years of surveillance prior to approval for clinical use (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-117
Reproducibility of Cefiderocol-Xeruborbactam in Cation Adjusted Mueller Hinton Broth (CAMHB) and Iron Depleted (ID) CAMHB Using Two Reading Endpoints
Reproducibility of Cefiderocol-Xeruborbactam in Cation Adjusted Mueller Hinton Broth (CAMHB) and Iron Depleted (ID) CAMHB Using Two Reading Endpoints. Lead author: Mariana Castanheira, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-172
Activity of Cefiderocol-Xeruborbactam and Comparator Agents against Pseudomonas aeruginosa, Including Molecularly Characterized Isolates Recovered Globally in 2024
Activity of Cefiderocol-Xeruborbactam and Comparator Agents against Pseudomonas aeruginosa, Including Molecularly Characterized Isolates Recovered Globally in 2024. Lead author: KM Papp-Wallace, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-168
Activity of manogepix against mold isolates across geographic regions
Activity of manogepix against mold isolates across geographic regions. Lead author: Marisa L Winkler, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-18
Activity of manogepix against Aspergillus spp. isolates with CYP51 alterations
Activity of manogepix against Aspergillus spp. isolates with CYP51 alterations. Lead author: Marisa L Winkler, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-17
Antimicrobial Susceptibility of KPC-Producing Enterobacterales and Molecular Characterization of Ceftazidime-Avibactam-Resistant Strains from United States Medical Centers (2018–2025)
Antimicrobial Susceptibility of KPC-Producing Enterobacterales and Molecular Characterization of Ceftazidime-Avibactam-Resistant Strains from United States Medical Centers (2018–2025). Lead author: Helio S. Sader, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-116
Activity of IV fosfomycin against Enterobacterales collected from US medical centers during 2020–2023
Activity of IV fosfomycin against Enterobacterales collected from US medical centers during 2020–2023. Lead author: KM Papp-Wallace, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-169
In vitro Activity of Cefiderocol Against a Collection of Infrequently Isolated Gram-Negative Bacterial Isolates from the SENTRY Antimicrobial Surveillance Program
In vitro Activity of Cefiderocol Against a Collection of Infrequently Isolated Gram-Negative Bacterial Isolates from the SENTRY Antimicrobial Surveillance Program. Lead author: Joshua M. Maher, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-141
Antimicrobial Activity of Aztreonam-Avibactam against Enterobacterales Isolated from Patients with Ventilator-Associated Pneumonia (VAP)
Antimicrobial Activity of Aztreonam-Avibactam against Enterobacterales Isolated from Patients with Ventilator-Associated Pneumonia (VAP). Lead author: Mariana Castanheira, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-132
Activity of manogepix against yeast and mold isolates from 2025 in the United States
Activity of manogepix against yeast and mold isolates from 2025 in the United States. Lead author: Marisa L Winkler, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-19
Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in United States Medical Centers (2023–2025)
Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in United States Medical Centers (2023–2025). Lead author: Helio S. Sader, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-118
Activity of rezafungin against Aspergillus spp. that are non-wild-type to azole antifungal agents
Activity of rezafungin against Aspergillus spp. that are non-wild-type to azole antifungal agents. Lead author: Marisa L Winkler, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-20
Activity of cefiderocol-xeruborbactam and comparator agents against global Acinetobacter baumannii-calcoaceticus species complex isolates
Activity of cefiderocol-xeruborbactam and comparator agents against global Acinetobacter baumannii-calcoaceticus species complex isolates. Lead author: John H. Kimbrough, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-167
Activity of Ceftazidime-Avibactam against Pseudomonas aeruginosa from Patients with Ventilator-Associated Pneumonia (VAP) from United States Medical Centers (2021–2025)
Activity of Ceftazidime-Avibactam against Pseudomonas aeruginosa from Patients with Ventilator-Associated Pneumonia (VAP) from United States Medical Centers (2021–2025). Lead author: Helio S. Sader, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-115
In Vitro Activity of Ceftobiprole and Comparator Agents Against Contemporary U.S. Clinical Isolates Collected in 2025 Following FDA Approval
In Vitro Activity of Ceftobiprole and Comparator Agents Against Contemporary U.S. Clinical Isolates Collected in 2025 Following FDA Approval. Lead author: Rodrigo E. Mendes, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-142
Activity of Cefiderocol-Xeruborbactam and Comparator Agents against Enterobacterales, Including Molecularly Characterized Isolates Recovered Globally in 2024
Activity of Cefiderocol-Xeruborbactam and Comparator Agents against Enterobacterales, Including Molecularly Characterized Isolates Recovered Globally in 2024. Lead author: KM Papp-Wallace, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-166
Activity of Aztreonam-Avibactam and Comparators against Difficult-to- Treat Resistant (DTR) Enterobacterales from Patients with Pneumonia or Intra-abdominal Infections (IAI) in European Medical Centers (2020-2024)
Activity of Aztreonam-Avibactam and Comparators against Difficult-to- Treat Resistant (DTR) Enterobacterales from Patients with Pneumonia or Intra-abdominal Infections (IAI) in European Medical Centers (2020-2024). Lead author: Helio S. Sader, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #1273
Activity of manogepix against Candida auris
Activity of manogepix against Candida auris. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3308
Activity of Zosurabalpin Against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) Isolates Producing NDM and/or Oxacillinase Enzymes
Activity of Zosurabalpin Against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) Isolates Producing NDM and/or Oxacillinase Enzymes. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #1351
Activity of manogepix against invasive fungal infections from immunocompromised hosts
Activity of manogepix against invasive fungal infections from immunocompromised hosts. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3309
Activity of mold-active azole agents against Aspergillus fumigatus clinical isolates nonwildtype to azoles and isolates displaying CYP51 alterations
Activity of mold-active azole agents against Aspergillus fumigatus clinical isolates nonwildtype to azoles and isolates displaying CYP51 alterations. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3323
Activity of Manogepix and Comparator Antifungals Against Mould Isolates Collected from Invasive Infections in Intensive Care Units (ICU) and Non-ICU Settings (2017–2024)
Activity of Manogepix and Comparator Antifungals Against Mould Isolates Collected from Invasive Infections in Intensive Care Units (ICU) and Non-ICU Settings (2017–2024). Lead author: Michael Huband, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3320
Characterization of Candida auris (Candidozyma auris) from a worldwide surveillance program over 12 years
Characterization of Candida auris (Candidozyma auris) from a worldwide surveillance program over 12 years. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3305
Activity of Manogepix and Comparator Antifungal Agents Against Yeast Isolates Collected from Invasive Infections in Intensive Care Unit (ICU) and Non-ICU Settings
Activity of Manogepix and Comparator Antifungal Agents Against Yeast Isolates Collected from Invasive Infections in Intensive Care Unit (ICU) and Non-ICU Settings. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3310
Occurrences by Region and Age Groups and Antifungal Susceptibility Profiles of Opportunistic Filamentous Fungal Pathogens Collected in 8 Years of Global Surveillance
Occurrences by Region and Age Groups and Antifungal Susceptibility Profiles of Opportunistic Filamentous Fungal Pathogens Collected in 8 Years of Global Surveillance. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3323
Isavuconazole activity against moulds in ICU and non-ICU infections
Isavuconazole activity against moulds in ICU and non-ICU infections. Lead author: SJ Ryan Arends, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3303
Comparison of manogepix activity against 2,659 community-acquired and nosocomial mould isolates from the SENTRY Antimicrobial Surveillance Program (2017–2024)
Comparison of manogepix activity against 2,659 community-acquired and nosocomial mould isolates from the SENTRY Antimicrobial Surveillance Program (2017–2024). Lead author: Michael Huband, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3309
Lefamulin Activity against Bacterial Pathogens Typically Causing Community-Acquired Pneumonia Collected from European Medical Centres in 2023 and 2024
Lefamulin Activity against Bacterial Pathogens Typically Causing Community-Acquired Pneumonia Collected from European Medical Centres in 2023 and 2024. Lead author: Helio S. Sader, presented at ESCMID Global 2026, April 20, Munich, Germany
P #1245
Activity of rezafungin against Aspergillus spp.
Activity of rezafungin against Aspergillus spp. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3304
Isavuconazole activity against moulds in nosocomial and community-acquired infections
Isavuconazole activity against moulds in nosocomial and community-acquired infections. Lead author: SJ Ryan Arends, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3312
Activity of tebipenem against Enterobacterales, including molecularly characterized isolates causing urinary tract and bloodstream infections in the United States and United Kingdom in 2023-2024
Activity of tebipenem against Enterobacterales, including molecularly characterized isolates causing urinary tract and bloodstream infections in the United States and United Kingdom in 2023-2024. Lead author: Timothy Doyle, presented at ESCMID Global 2026, April 19, Munich, Germany
Poster #2644
In vitro Activity of Zosurabalpin and Comparator Agents Tested Against Acinetobacter baumannii-calcoaceticus Complex Isolates From China
In vitro Activity of Zosurabalpin and Comparator Agents Tested Against Acinetobacter baumannii-calcoaceticus Complex Isolates From China. Lead author: Joshua M. Maher, presented at APCCMI 2025, Nov 3, Bangkok, Thailand
Poster #RES-162
Activity of Zosurabalpin and Comparator Antimicrobial Agents Tested Against Acinetobacter baumannii-calcoaceticus Complex (ABC) Isolates Collected Worldwide in 2024
Activity of Zosurabalpin and Comparator Antimicrobial Agents Tested Against Acinetobacter baumannii-calcoaceticus Complex (ABC) Isolates Collected Worldwide in 2024. Lead author: Joshua M. Maher, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1333
Activity of manogepix against surveillance yeast isolates collected from the United States in 2023
Activity of manogepix against surveillance yeast isolates collected from the United States in 2023. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1195
In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024
In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024. Lead authors: R Kapoor, TB Doyle, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1214
Geographic distribution, MIC testing, and susceptibility rates of Candida auris isolates collected in the United States since 2014
Geographic distribution, MIC testing, and susceptibility rates of Candida auris isolates collected in the United States since 2014. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1196
Five-year trend analysis of carbapenem-resistant Enterobacterales, including isolates carrying metallo-β-lactamase genes in United States, Europe and adjacent regions during 2020–2024
Five-year trend analysis of carbapenem-resistant Enterobacterales, including isolates carrying metallo-β-lactamase genes in United States, Europe and adjacent regions during 2020–2024. Lead author: Mariana Castanheira, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1279
A 10-year Trend on Antimicrobial Resistance of Pseudomonas aeruginosa from United States Medical Centers: Results from the INFORM Surveillance Program (2015–2024)
A 10-year Trend on Antimicrobial Resistance of Pseudomonas aeruginosa from United States Medical Centers: Results from the INFORM Surveillance Program (2015–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1313
In Vitro Activity of Cefiderocol against Resistant Subsets of Pseudomonas aeruginosa Collected from United States Hospitals during 2020–2024
In Vitro Activity of Cefiderocol against Resistant Subsets of Pseudomonas aeruginosa Collected from United States Hospitals during 2020–2024. Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1287
Activity of Aztreonam-Avibactam and Comparators against Difficult-to-Treat Resistant (DTR) Enterobacterales from United States Medical Centers (2020–2024)
Activity of Aztreonam-Avibactam and Comparators against Difficult-to-Treat Resistant (DTR) Enterobacterales from United States Medical Centers (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1316
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized ESBL- and carbapenemase-positive subsets causing urinary tract infections in United States Medical Centers (2023)
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized ESBL- and carbapenemase-positive subsets causing urinary tract infections in United States Medical Centers (2023). Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1203
Antimicrobial Activity of Aztreonam-Avibactam and Molecular Characterization of Enterobacterales Resistant to Ceftazidime-Avibactam and/or Meropenem-Vaborbactam from United States Medical Centers (2016–2024)
Antimicrobial Activity of Aztreonam-Avibactam and Molecular Characterization of Enterobacterales Resistant to Ceftazidime-Avibactam and/or Meropenem-Vaborbactam from United States Medical Centers (2016–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1319
Performance of the VITEK 2 with Advance Expert System as a Fast Method for Determination of Antimicrobial Susceptibility Against 400 Enterobacterales Isolates from North America and Latin America (2022)
Performance of the VITEK 2 with Advance Expert System as a Fast Method for Determination of Antimicrobial Susceptibility Against 400 Enterobacterales Isolates from North America and Latin America (2022). Lead author: Michael D. Huband, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1697
Activity of Delafloxacin and Comparator Agents Against Bacterial Isolates from Patients with Diabetic Foot Infection in the United States and Europe (2017–2023)
Activity of Delafloxacin and Comparator Agents Against Bacterial Isolates from Patients with Diabetic Foot Infection in the United States and Europe (2017–2023). Lead author: Michael D. Huband, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1340
Antimicrobial susceptibility of S. maltophilia and B. cepacia species complex isolated from patients with pneumonia in United States hospitals (2022–2024)
Antimicrobial susceptibility of S. maltophilia and B. cepacia species complex isolated from patients with pneumonia in United States hospitals (2022–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1320
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from Europe, Asia, and Latin America (2020–2024)
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from Europe, Asia, and Latin America (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1314
Activity of isavuconazole against contemporary Mucorales from a worldwide surveillance program
Activity of isavuconazole against contemporary Mucorales from a worldwide surveillance program. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1193
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents Tested against Enterobacterales from European Hospitals Analysed by Infection Type (2022–2024)
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents Tested against Enterobacterales from European Hospitals Analysed by Infection Type (2022–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1317
Activity of aztreonam-avibactam tested against genetically characterized non-carbapenemase-producing carbapenem-resistant Enterobacterales
Activity of aztreonam-avibactam tested against genetically characterized non-carbapenemase-producing carbapenem-resistant Enterobacterales. Lead author: Mariana Castanheira, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1332
